Last Updated on October 2, 2024 by The Health Master
European Medicines Agency
In the rapidly evolving landscape of healthcare, the European Medicines Agency (EMA) and Heads of Medicines Agencies (HMAs) have taken a significant stride by unveiling a comprehensive plan.
This plan, designed in collaboration, aims to harness the full potential of artificial intelligence (AI) in the regulation of medicines.
The roadmap, extending until 2028, charts a course for the European medicines regulatory network (EMRN) to leverage AI for enhanced productivity, automated processes, data insights, and robust decision-making.
The AI Workplan: A Closer Look
Originating from the Big Data Steering Group (BDSG), a joint initiative of HMA and European Medicines Agency (EMA), the AI workplan has been adopted by EMA’s Management Board in its December meeting.
This strategic initiative is positioned to keep the EMRN at the forefront of AI’s benefits in medicines regulation.
Let’s delve into the four key dimensions of this groundbreaking AI workplan.
Dimensions of the AI Workplan
Guidance, Policy, and Product Support
- Continuous support for products in development
- Development and evaluation of guidance for AI in medicine lifecycle
- Ongoing public consultation on the AI reflection paper
- Preparations for EU AI Act implementation in 2024
AI Tools and Technology
- Identifying and providing frameworks for AI tools
- Ensuring compliance with data protection legislation
- Enhancing efficiency and decision-making through AI
Collaboration and Training
- Initiatives to develop the capacity of the network and stakeholders
- Keeping ahead of the evolving field of AI
- Continuous development of skills and capabilities
Experimentation
- Acknowledging the role of experimentation in AI development
- Structured approach to experimentation across the network
- Actions proposed for accelerated learning and insights
Fast Evolution of AI Technology
As AI technology evolves rapidly, including ethical and policy aspects, the BDSG is committed to regularly updating the workplan.
This proactive approach ensures that the EMRN stays abreast of the latest developments, maintaining a balance between innovation and ethical considerations.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issues Form 483 with 5 observations to Moderna
FDA Maharashtra: Overhauling the Drug Regulatory System
Drug recall: Unraveling the recall by Sun and Lupin
Indian Pharma’s Commitment to Drug Quality, Patient Safety, and Regulatory Compliance
Maharashtra FDA’s Crackdown: Strengthening Pharmaceutical Compliance
DCOIWA successfully organised workshop on Risk Based Inspection: Ahmedabad
USFDA Approval granted for Cyclophosphamide Capsules: Zydus
New Drug Permissions and Launches should be made public
CDSCO approval granted for Inhalation Aerosol: AstraZeneca
FDA Maharashtra to recruit 750 officials soon
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
